BiotechTube

Cholic Acids

Phase 3Completed
0 watching 0 views this week📈 Rising
74
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Infantile Refsum's Disease

Conditions

Infantile Refsum's Disease, Zellweger Syndrome, Adrenoleukodystrophy, Peroxisomal Disorders, Cholestasis

Trial Timeline

Jan 1, 1992 → Dec 1, 2009

NCT ID
NCT00007020

About Cholic Acids

Cholic Acids is a phase 3 stage product being developed by Mirum Pharmaceuticals for Infantile Refsum's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00007020. Target conditions include Infantile Refsum's Disease, Zellweger Syndrome, Adrenoleukodystrophy.

Hype Score Breakdown

Clinical
27
Activity
18
Company
7
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT00007020Phase 3Completed

Competing Products

16 competing products in Infantile Refsum's Disease

See all competitors
ProductCompanyStageHype Score
TSHA-101Taysha Gene TherapiesPhase 1/2
36
MAS825 + PlaceboNovartisPhase 2
52
alglucosidase alfa + alglucosidase alfaSanofiApproved
84
MyozymeSanofiPhase 2
51
Bacillus Clausii Multi ATB Resist + PlaceboSanofiApproved
84
RadiprodilUCBPhase 2
49
Larotrectinib (Vitrakvi, BAY2757556) + Standard of CareBayerPre-clinical
20
Sabril®LundbeckPre-clinical
20
VigabatrinLundbeckApproved
82
NusinersenBiogenPre-clinical
20
GWP42003-PJazz PharmaceuticalsPhase 3
74
GWP42003-PJazz PharmaceuticalsPhase 3
74
Cerliponase AlfaBioMarin PharmaceuticalPre-clinical
20
Cipaglucosidase alfa + MiglustatAmicus TherapeuticsPhase 3
74
ATB200 + AT2221Amicus TherapeuticsPre-clinical
20
RP-L401Rocket PharmaceuticalsPhase 1
25

Other Products from Mirum Pharmaceuticals

Livmarli Oral ProductApproved
82
MaralixibatPhase 3
74
MaralixibatPhase 3
74
Cholic acidPhase 3
74
Brelovitug 300 mg + Bulevirtide 2 mg and Brelovitug - 300 mgPhase 3
74